Arthritis News and Research

Latest Arthritis News and Research

Reduce inflammatory reaction by losing weight, says researcher

Researchers have found a possible molecular explanation for why overweight is harmful. This new knowledge may provide new drugs for heart attack, stroke, cancer and chronic intestinal inflammation.

25 Aug 2014

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that details from four pivotal trials in the alirocumab ODYSSEY clinical program will be presented on Sunday, August 31, during a Hot Line session at ESC Congress 2014 in Barcelona, Spain, the world's largest cardiology meeting.

25 Aug 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

A new study finds a wide range of epigenetic changes-alterations in DNA across the genome that may be related to key environmental exposures-in children with Crohn's disease (CD), reports Inflammatory Bowel Diseases, official journal of the Crohn's & Colitis Foundation of America.

23 Aug 2014

Race and ethnicity influence outcomes of patients with motor complete SCI

Researchers have published a study examining racial and ethnic influences in the outcomes of patients with motor complete spinal cord injury (SCI). The article, "Racial and ethnic disparities in functioning at discharge and follow-up among patients with motor complete SCI," was published online ahead of print on August 2 by the Archives of Physical Medicine & Rehabilitation.

22 Aug 2014

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Researchers have discovered that three commonly used nonsteroidal anti-inflammatory drugs, or NSAIDs, alter the activity of enzymes within cell membranes. Their finding suggests that, if taken at higher-than-approved doses and/or for long periods of time, these prescription-level NSAIDs and other drugs that affect the membrane may produce wide-ranging and unwanted side effects.

22 Aug 2014

Highlights from the August issue of Mayo Clinic Health Letter

Here are highlights from the August issue of Mayo Clinic Health Letter. You may cite this publication as often as you wish. Reprinting is allowed for a fee. Mayo Clinic Health Letter attribution is required.

22 Aug 2014

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Eli Lilly and Company's investigational medicine ixekizumab was statistically superior to etanercept and placebo on all skin clearance measures in Phase 3 studies, the company said today in disclosing top-line results from its pivotal UNCOVER studies in moderate-to-severe plaque psoriasis.

22 Aug 2014

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody.

20 Aug 2014

Researchers shed light on the dual action of aspirin

Hugely popular non-steroidal anti-inflammation drugs like aspirin, naproxen (marketed as Aleve) and ibuprofen (Advil, Motrin) all work by inhibiting or killing an enzyme called cyclooxygenase - a key catalyst in production of hormone-like lipid compounds called prostaglandins that are linked to a variety of ailments, from headaches and arthritis to menstrual cramps and wound sepsis.

19 Aug 2014

AMGF participates in collaborative effort to find best practices in managing RA patients

The American Medical Group Foundation today announced participants in a collaborative dedicated to finding best practices in managing patients with rheumatoid arthritis (RA).

19 Aug 2014

Research findings call for clinical testing of relevant drugs to prevent NASH

Non-alcoholic fatty liver disease (NAFLD) is a common affliction, affecting almost 30 percent of Americans, with a significant number suffering from its most severe form, called non-alcoholic steatohepatitis or NASH, which can lead to cirrhosis and liver cancer. In recent years, NASH has become the leading cause of liver transplantation.

19 Aug 2014

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Decision Resources has expanded its disease-level coverage of the Treatment Algorithms Insight Series, which examines U.S. physicians' prescribing behavior, to provide a quantitative analysis of an agent's penetration into each line of therapy.

19 Aug 2014

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

The Centers for Medicare & Medicaid Services within the Department of Health and Human Services has taken steps to prevent its contractors from conducting certain duplicative postpayment claims reviews - reviews of the same claims that are not permitted by the agency - but CMS neither has reliable data nor provides sufficient oversight and guidance to measure and fully prevent duplication.

16 Aug 2014

Research shows new drug candidate can stop tumor growth in animal models

It's a trick any cat burglar knows: to open a locked door, slide a credit card past the latch. Scientists at The Scripps Research Institute (TSRI) tried a similar strategy when they attempted to disrupt the function of MYC, a cancer regulator thought to be "undruggable."

12 Aug 2014

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Experts believe a molecule in parasitic worms could help explain why worm infections can effectively treat a range of autoimmune diseases, including multiple sclerosis, psoriasis, rheumatoid arthritis and lupus.

12 Aug 2014

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

A recent study by investigators at VIB and KU Leuven has demonstrated that chloroquine also normalizes the abnormal blood vessels in tumors. This blood vessel normalization results in an increased barrier function on the one hand -- thereby blocking cancer cell dissemination and metastasis -- and in enhanced tumor perfusion on the other hand, which increases the response of the tumor to chemotherapy.

11 Aug 2014

Black and Hispanic SLE patients are more likely to be readmitted than white patients

A new study reveals that one in six patients with systemic lupus erythematosus (SLE) is readmitted to the hospital within 30 days of being discharged.

11 Aug 2014

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

Regeneron Pharmaceuticals, Inc. today announced that EYLEA® (aflibercept) Injection has been approved by the European Commission for the treatment of visual impairment due to Diabetic Macular Edema.

11 Aug 2014

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

3SBio Inc., a leading China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, today announced it has entered into an exclusive license with DiNonA Inc. for the development, manufacturing and marketing of Leukotuximab, an anti JL-1 antibody for acute leukemia (AL), including acute myelocytic leukemia (AML) and acute lymphoblastic leukemia (ALL), in the territory of Greater China (including Mainland China, Taiwan, Hong Kong and Macau) and the Middle East (excluding Cyprus, Egypt, Israel and Turkey).

8 Aug 2014

Idera collaborates with TMA to advance new potential treatment approach for myositis

Idera Pharmaceuticals, Inc., a clinical stage biopharmaceutical company developing nucleic acid therapeutics for patients with cancer and rare diseases, and The Myositis Association (TMA), the only nonprofit organization dedicated to solely serving all patients with inflammatory myopathies, today announced a collaboration to advance a new potential treatment approach for polymyositis and dermatomyositis known as Toll-like receptor (TLR) antagonism.

7 Aug 2014

Arthritis News and Research

Latest Arthritis News and Research

Reduce inflammatory reaction by losing weight, says researcher

Sanofi, Regeneron present alirocumab Phase 3 trial results at ESC Congress 2014

Study finds a host of new clues on gene-environment interactions in Crohn's disease

Race and ethnicity influence outcomes of patients with motor complete SCI

Three commonly used NSAIDs affect cell membranes, produce unwanted side effects

Highlights from the August issue of Mayo Clinic Health Letter

Lilly’s ixekizumab superior to placebo, etanercept on all skin clearance measures in Phase 3 studies

Glenmark announces discovery and initiation of IND enabling studies of innovative bispecific antibody

Researchers shed light on the dual action of aspirin

AMGF participates in collaborative effort to find best practices in managing RA patients

Research findings call for clinical testing of relevant drugs to prevent NASH

Decision Resources expands disease-level coverage of Treatment Algorithms Insight Series

Research roundup: Benefits of smaller practices; Rx price growth; fixing Medicare claims reviews

Research shows new drug candidate can stop tumor growth in animal models

Experts examine how molecule in parasitic worms can effectively treat autoimmune diseases

Antimalarial agent chloroquine normalizes abnormal tumor blood vessels

Black and Hispanic SLE patients are more likely to be readmitted than white patients

European Commission approves EYLEA Injection for treatment of visual impairment due to DME

3SBio enters into exclusive license with DiNonA for development of Leukotuximab

Idera collaborates with TMA to advance new potential treatment approach for myositis

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Arthritis News and Research

Latest Arthritis News and Research

Innovating for impact: Jordi Labs on aligning methodologies with FDA expectation

Exploring the role of confocal-based high-content imaging in advancing core facilities

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Newsletters you may be interested in